Clinical Trial Update: Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT [Phase 2]

View source ↗

Summary

Phase II trial update examining maintenance subcutaneous rituximab after induction in relapsed mantle cell lymphoma and non-eligible for hematopoietic stem cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Mantle-cell Lymphoma | Phase 2 | Status: UNKNOWN